Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities

摘要

Results of the Hermine study of trastuzumab beyond progression in breast cancer patients, published by Extra and colleagues in The Oncologist, are re-examined and an alternative explanation for the dismal postprogression survival time of patients stopping therapy is presented.